Labcorp and Children’s Hospital of Philadelphia Partner to Expand Pediatric Diagnostic Access
The collaboration aims to create an innovation pipeline for specialized pediatric tests across oncology, metabolic disease, and autoimmune conditions.
The collaboration aims to create an innovation pipeline for specialized pediatric tests across oncology, metabolic disease, and autoimmune conditions.
Caris Life Sciences has launched Caris ChromoSeq, a whole genome and transcriptome sequencing assay for myeloid malignancies, designed to consolidate multiple tests into a single workflow with a seven-day turnaround.
A retrospective study in Lymphatics reports that CSF liquid biopsy testing delivered clinical impact in 82% of CNS lymphoma cases, resolving diagnoses and informing treatment when standard methods were inconclusive.
Ibex Medical Analytics has launched Ibex 4, an AI-powered pathology platform with expanded end-to-end breast cancer diagnostic workflows, zero-click IHC tools, and enhanced lab integration capabilities for increased efficiency.
Read MoreThe Pennsylvania-based laboratory will integrate Ibex’s AI solution for prostate biopsies and TURP specimens into its existing digital pathology infrastructure.
Read MoreResearchers found that circulating tumor DNA testing could identify which older patients with estrogen receptor–positive breast cancer are less likely to respond to hormone therapy alone.
Read MoreThe Bloodhound BCR::ABL1 assay simultaneously detects and quantifies all four clinically important isoforms in a single run, offering new capabilities for chronic myeloid leukemia management.
Read MoreThe initiative gives eligible pharmacy customers a streamlined pathway to request the Cologuard stool DNA test, with no prep or special diet required.
Read MoreHepion Pharmaceuticals has licensed a circulating tumor RNA assay from Cirna Diagnostics for early detection of hepatocellular carcinoma in high-risk patients, expanding its liquid biopsy portfolio for liver cancer.
Read More20/20 BioLabs argues a tiered screening approach—starting with protein-based tests before moving to circulating tumor DNA testing or imaging—could improve early-stage detection and lower costs.
Read MoreData show the test can predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Read MorePhysicians can now order the Shield blood test through Quest’s network of nearly 650,000 clinician and hospital accounts, patient service centers, and in-office phlebotomists.
Read MoreA study reports that dual epigenetic markers in cell-free DNA achieved 95% diagnostic accuracy for stage I colorectal cancer, outperforming conventional liquid biopsy methods.
Read MoreThe FDA has granted Breakthrough Device Designation to Breath Diagnostics Inc.’s OneBreath, a breath-based test that assesses postoperative pneumonia risk in cardiac surgery patients using a single preoperative sample.
Read MoreA multicenter study reports that combining fecal SDC2 methylation testing with the APCS scoring system improves advanced adenoma detection and specificity in colorectal cancer screening.
Read MoreResearchers have identified blood-based metabolic signatures that may enable earlier, noninvasive detection of gallbladder cancer, according to findings in the Journal of Proteome Research.
Read MoreVeracyte will present over 15 studies on its Decipher prostate and bladder cancer tests, including new clinical trial data, at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco.
Read MoreThe integrated testing approach combines genomic profiling with immunohistochemistry to support faster treatment decisions for advanced-stage cancer patients.
Read More